Objective To explore the efficacy and safety of intermittent cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy(HIPEC)in the treatment of advanced ovarian cancer.Methods Patients diagnosed with advanced ovarian cancer in the First Affiliated Hospital of Bengbu Medical University from November 2020 to September 2021 were selected.According to whether to use HIPEC,the patients were divided into an experimental group and a con-trol group,with 45 cases in each group.The short-term outcomes and incidence of adverse effects after surgery and chem-otherapy in two groups of patients were compared.Results The objective response rate(ORR)was 86.7％in the ex-perimental group and 68.9％in the control group(P=0.043).The 2-year survival rate was 86.7％in the experimental group and 64.4％in the control group(P=0.014).The average progression-free survival(PFS)of the experimental group was(29.03±1.07)months,which was significantly higher than the control group[(16.60±1.12)months,P＜0.001].The adverse reactions after chemotherapy in the two groups were statistically significant in nausea/vomiting(P＜0.05),and liver function injury(P＜0.05).The incidences of abdominal distension and hypoproteinemia were 57.8％and 37.8％in the experimental group,and 2.2％and 2.2％in the control group,respectively(P＜0.05).Conclusion The use of intermittent cytoreductive surgery combined with HIPEC is expected to improve the short-term treatment effect of patients with advanced ovarian cancer within a controlled range and ensure the safety of treatment.
维普
万方数据